Literature DB >> 7389819

The effects of alinidine, an N-allyl derivative of clonidine, on regional myocardial perfusion and performance in the pig with or without atrial pacing.

P D Verdouw, P R Saxena, H C Schamhardt, T M van der Hoek, A M Rutteman.   

Abstract

The effects of alinidine (0.2-6.0 mg . kg-1), an N-allyl derivative of clonidine, were investigated on systemic and regional haemodynamics, in particular myocardial perfusion and performance in the domestic pig, during or in the absence of atrial pacing. The drug had a pronounced bradycardic action and also caused dose-dependent reductions in the maximum rate of rise in left ventricular pressure (max LVdP/dt) cardiac output (CO), arterial blood pressure and in the mean velocity of systolic wall thickening (VSWT) in the absence of atrial pacing. Since the duration of systole was prolonged by alinidine, the total wall thickening during systole (SWT) remained unchanged until the highest dose was given. When the heart rate was kept constant by atrial pacing, there were no changes in the maxLVdP/dt, CO or VSWT with with lower doses (less than 0.4 mg . kg-1) of alinidine. With higher doses, however, there was a significant reduction in these variables, demonstrating a clear negative inotropic action of the drug. The decrease in CO was entirely at the expense of its nutrient fraction (NCO), since systemic arteriovenous anastomotic flow remained unchanged. However, the reduction in NCO did not hamper tissue oxygenation either because of autoregulation within blood vessels (cerebral and renal), or because the tissues were able to extract more O2 from the blood. Similarly, despite the reduction of myocardial perfusion, no imbalance in the myocardial oxygen supply-demand relationship was noticed due to a simultaneous reduction of the myocardial work in both unpaced and paced hearts. Moreover, the changes in the intramyocardial blood flow were quite uniform. It is concluded that alinidine has a negative chronotropic and, in higher doses, a negative inotropic action. The cardiovascular profile of the drug suggests that it could be useful in patients with ischaemic heart disease.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7389819     DOI: 10.1016/0014-2999(80)90228-9

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  8 in total

1.  The selective bradycardic effects of zatebradine (UL-FS 49) do not adversely affect left ventricular function in conscious pigs with chronic coronary artery occlusion.

Authors:  L J van Woerkens; W J van der Giessen; P D Verdouw
Journal:  Cardiovasc Drugs Ther       Date:  1992-02       Impact factor: 3.727

2.  Iloprost (ZK 36374) enhances recovery of regional myocardial function during reperfusion after coronary artery occlusion in the pig.

Authors:  W J van der Giessen; B Schoutsen; J G Tijssen; P D Verdouw
Journal:  Br J Pharmacol       Date:  1986-01       Impact factor: 8.739

3.  Systemic and regional myocardial responses to AR-L 115 BS, a positive inotropic imidazo-pyridine, in the absence or in the presence of the bradycardiac action of alinidine.

Authors:  P D Verdouw; J M Hartog; A M Ruggeman
Journal:  Basic Res Cardiol       Date:  1981 May-Jun       Impact factor: 17.165

4.  Decreased incidence of ventricular fibrillation after an acute coronary artery ligation in exercised pigs.

Authors:  M G Scheffer; P D Verdouw
Journal:  Basic Res Cardiol       Date:  1983 May-Jun       Impact factor: 17.165

5.  Redistribution by 5-hydroxytryptamine of carotid arterial blood at the expense of arteriovenous anastomotic blood flow.

Authors:  P R Saxena; P D Verdouw
Journal:  J Physiol       Date:  1982-11       Impact factor: 5.182

6.  Electropharmacology of the bradycardic agents alinidine and zatebradine (UL-FS 49) in a conscious canine ventricular arrhythmia model of permanent coronary artery occlusion.

Authors:  I Aidonidis; J Brachmann; I Rizos; A Zacharoulis; I Stavridis; P Toutouzas; W Kübler
Journal:  Cardiovasc Drugs Ther       Date:  1995-08       Impact factor: 3.727

7.  The central and regional cardiovascular responses to intravenous and intracoronary administration of the phenyldihydropyridine elgodipine in anaesthetized pigs.

Authors:  L M Sassen; L K Soei; M M Koning; P D Verdouw
Journal:  Br J Pharmacol       Date:  1990-02       Impact factor: 8.739

8.  Comparative effects of alinidine and propranolol in ischaemic heart disease.

Authors:  J Schurmans; J Piessens; H Kesteloot; H De Geest
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.